| Bioactivity | TI17 is an inhibitor of the thyroid hormone receptor-interacting protein Trip13 and has anticancer activity. TI17 effectively inhibits multiple myeloma (MM) cell proliferation and induces cell cycle arrest and apoptosis. Trip13 is an AAA-ATPase that mediates double-strand break (DSB) repair; TI17 inhibits Trip13 function and increases DNA damage[1]. | ||||||||||||
| Target | Thyroid hormone receptor interacting protein 13 (Trip13) | ||||||||||||
| Name | TI17 | ||||||||||||
| CAS | 1005178-02-8 | ||||||||||||
| Formula | C23H22N2O3 | ||||||||||||
| Molar Mass | 374.43 | ||||||||||||
| Appearance | 固体 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Chang S et al. TI17, a novel compound, exerts anti-MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damage. Cancer Med. 2023 Nov 9. |